NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of NeuroVive Pharmaceutical (OTCMKTS:NEVPF) from a hold rating to a buy rating in a report published on Tuesday, reports. They currently have $0.25 target price on the stock.

According to Zacks, “NeuroVive Pharmaceutical AB is engaged in the research, discovery and development of mitochondrial-protecting pharmaceuticals. The company’s drug candidate consists of CicloMulsion(R) and NeuroSTAT(R) in clinical phases. CicloMulsion(R) is being studied for preoperative treatment of acute kidney injury coincident with major surgery and NeuroSTAT(R) is being studied for treating traumatic brain injury. NeuroVive Pharmaceutical AB is headquartered in Lund, Sweden. “

OTCMKTS:NEVPF opened at $0.19 on Tuesday. The firm has a market capitalization of $9.94 million, a price-to-earnings ratio of -1.73 and a beta of 1.98. NeuroVive Pharmaceutical has a 1-year low of $0.10 and a 1-year high of $0.51. The business’s fifty day moving average price is $0.22 and its 200 day moving average price is $0.17.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases.

Recommended Story: How dollar cost averaging works

Get a free copy of the Zacks research report on NeuroVive Pharmaceutical (NEVPF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NeuroVive Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroVive Pharmaceutical and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit